Vaccination against human papilloma virus in mensituation and proposals

  1. Javier Cortés 1
  2. Ángel Gil 2
  3. Federico Martinón 36
  4. Francisco Xavier Bosch 47
  5. José Manuel Ramón y Cajal 5
  1. 1 Royal Academy of Medicine of the Balearic Islands.
  2. 2 Rey Juan Carlos University.
  3. 3 Pediatric Service. University Clinical Hospital of Santiago de Compostela.
  4. 4 Institute Catalá Oncología
    info

    Institute Catalá Oncología

    Barcelona, España

    ROR https://ror.org/01j1eb875

  5. 5 Gynecology Service. Hospital of San Jorge, Huesca
  6. 6 Group of Genetics, Vaccines, Infections and Pediatrics. Sanitary Research Institute of Santiago de Compostela.
  7. 7 Universitat Oberta de Catalunya
    info

    Universitat Oberta de Catalunya

    Barcelona, España

    ROR https://ror.org/01f5wp925

Show affiliations +
Journal:
Academic Journal of Health Sciences: Medicina Balear

ISSN: 2255-0560

Year of publication: 2022

Volume: 37

Issue: 3

Pages: 166-170

Type: Article

DOI: 10.3306/AJHS.2022.37.03.166 DIALNET GOOGLE SCHOLAR lock_openIbdigital editor

Abstract

The causal epidemiology of papillomavirus pathology in man and its incidence and the status of its preventive activity in Spain are described, which does not conform to the recommendation that scientific evidence has formulated and that many countries in our environment are following. Lines of action are detailed in this regard that are considered preferred from the point of view of health political action.

Bibliographic References

  • Kjaer SK, Chackerian B, van den Brule AJ, Svare EI, Paull G, Walbomers JM et al.: High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001; 10: 101-6
  • Available in https://www.who.int/es/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis) Access 01.08.2021.
  • Castellsagué X, Iftner T, Roura E, Vidart JA, Kjaer SK, Bosch FX et al.: Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study. J Med Virol. 2012; 84: 947-56.
  • Spanish Society of Epidemiology. Papilloma Virus and Cancer. Available in:https://www.seepidemiologia.es/documents/dummy/4monografiaVirusPapilomaYCancer.pdf. Access 02.08.2021
  • Szymonowicz KA, Chen J.: Biological and clinical aspects of HPV-related cancers Cancer Biol Med. 2020; 17: 864-78.
  • Available in:https://www.aecc.es/es/todo-sobre-cancer/que-es-cancer/factores-riesgo Access 02.08.2021.
  • López, N, Torné A, Franco A, San-Martín, M, Viayna E, Barrull C et al.: Epidemiologic and economic burden of HPV diseases in Spain: implication of additional 5 types from the 9-valent vaccine. Infect Agent Cancer. 2018; 13: 15.
  • Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-9.
  • Ghebreyesus TA, Director General.: Reunión Ejecutiva OMS Intercontinental Hotel, Genève, Confédération Suisse. 19 May 2018.
  • Cortés J, Bosch X, Concha A, González A, Martinón F, Ortiz de Lejarazu R et al.: Asociación Española contra el Cáncer: Documento de posición sobre prevención del Cáncer de Cuello de Útero. Prog Obstet Ginecol 2019; 61: 510-44.
  • Giuliano AR, Lazcano-Ponce E, Villa LL, Flores R, Salmeron J, Lee J-H et al.: The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2036-43
  • Ingles DJ, Lin HY, Fulp WJ, Sudenga SL, Lu B, Schabath MB et al.: An analysis of HPV infection incidence and clearance by genotype and age in men: The HPV Infection in Men (HIM) Study. Papillomavirus Res 2015; 1: 126-35
  • Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S.: Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010; 202: 1789-99.
  • Giuliano AR, Lee J-H, Fulp W, Villa LL, Lazcano-Ponce E, Papenfuss MR, Abrahamsen M et al.: Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011; 377: 932-40.
  • Albero G, Villa LL, Lazcano-Ponce E, Fulp W, Papenfuss MR, Nyitray AG et al.: Male circumcision and prevalence of genital human papillomavirus infection in men: a multinational study. BMC Infect Dis. 2013; 13: 18.
  • Chatuverdi AK, Engels EA, Pfeiffer RM, Hernández BY, Weihong X, Kim E et al.: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29: 4294-301.
  • Giuliano AR, Viscidi R, Torres N, Ingles DJ, Sudenga SL, Villa LL et al.: Seroconversion Following Anal and Genital HPV Infection in Men: The HIM Study. Papillomavirus Res. 2015; 1: 109-15.
  • Stanley M.: Program Research Epidemiology of Cancer. Cambridge Univ. Presented at EUROGIN 2018. 2-5 December. Lisbon. Portugal.
  • Cervarix® summary product characteristics. Available in https://cima.aemps.es/cima/dochtml/ft/07419004/FT_07419004.html Access 03.08.2021.
  • Gardasil9® summary product characteristics. Available in https://cima.aemps.es/cima/dochtml/ft/1151007002/FT_1151007002.html Access 03.08.2021.
  • Available in: https://search.usa.gov search?query=gardasil9+expanded&affiliate=fda1 Access 03.07.2021
  • Global Advisory Committee on Vaccine Safety (GACVS). Weekly Epidemiological Record: 92; 28. 14 de julio de 2017.
  • Majed L, Bresse X, El Mouaddin N, Schmidt A, Daniels VJ, Pavelyev et al.: Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France. Vaccine. 2021; 39: 438-46.
  • Simons JJM, Vida N, Westra TA, Postma MJ.: Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands. Vaccine. 2020; 38: 4687-94.
  • Qendri V, Bogaards JA, Baussano I, Lazzarato F, Vänskä S, Berkhof J.: The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment. Lancet Public Health. 2020; 5: e592 – e603.
  • Vänskä S, Luostarinen T, Baussano I, Apter D, Eriksson T, Natunen K et al.: Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. J Infect Dis. 2020; 222: 948-56.
  • Available in https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/vacunas/profesionales/vph.htm Access 27.08.2021.
  • Available in:https://vacunasaep.org/profesionales/noticias/VPH-informe-ECDC-vacunacion-varones-y-otros-temas Access 03.08.2021.
  • European Commission. Europe’s Beating Cancer Plan. Communication from the Commission to the European Parliament and the Council 2021. Available in: https://ec.europa.eu/health/sites/default/files/non_communicable_diseases/docs/eu_cancer-plan_en.pdf Access 27.08.2021
  • Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G.: Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009; 27: 127-47.
  • Available in: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/calendario-y-coberturas/coberturas/docs/Tabla11.pdf) Access 03.08.2021.
  • K Pollock (2019). Adolescent male vaccination in the United Kingdom - a victory for equality. www.HPVWorld.com, 94.
  • Linertová R, Guirado Fuentes C, Toledo Chávarri A, Vallejo Torres L, García Pérez L, Delgado Rodríguez J et al.: Vacuna frente a VPH en varones adolescentes: coste-efectividad e impacto presupuestario. Ministry of Health, Consumption and Social Welfare. Evaluation Service of the Canary Islands Health Service; 2020. Health Technology Assessment Reports.
  • Available in https://www.euskadi.eus/informacion/vacuna-contra-el-virus-del-papiloma/web01-a2adik/es/ Access 10.09.2021
  • Available in:https://saludcantabria.es/index.php?page=vacunaciones Access 10.09.2021
  • Available in:https://salutpublica.gencat.cat/web/.content/minisite/aspcat/promocio_salut/vacunacions/00manual_de_vacunacions/capitols_i_annexos_manual/apartat_4_vacunes_disponibles/Manual-Vacunacions-apartat-4_12.pdf Access 11.09.2021
  • Available in:https://www.saludcastillayleon.es/es/vacunaciones/vacunacion-frente-virus-papiloma-humano-vph-2019 Access 11.09.2021
  • Available in https://www.who.int/news/item/22-07-2021-vaccine-inequity-undermining-global-economic-recovery Access 02.09.2021.
  • Colzani E, Johansen K, Johnson H, Celentano LP.: Human papillomavirus vaccination in the European Union/European Economic Area and globally: a moral dilemma. Euro Surveill. 2021; 26(50).
  • Lehtinen M, Baussano I, Paavonen J, Vänska S, Dillner J.: Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies. Expert Rev Vaccines. 2019; 18: 153 – 160.
Data source: Dialnet